Puma Biotech (PBYI) Tops Q3 EPS by 13c, Misses on Revenue

Puma Biotech (NASDAQ: PBYI) reported Q3 EPS of $0.46, $0.13 better than the analyst estimate of $0.33. Revenue for the quarter came in at $80.5 million versus the consensus estimate of $70.65 million.

For earnings history and earnings-related data on Puma Biotech (PBYI) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• PreveCeutical closes second tranche of private placement for $245,000
• Lockheed Martin wins $2.8B in Defense contracts for F-35, helicopters